NCT05839119 2026-04-02
TASUC-Neo
Brown University
Phase 1 Terminated
Clinical Trials
19 trialsNCT03288545 2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2 Terminated
NCT01495676 2025-10-10
GETUGV04
Institut du Cancer de Montpellier - Val d'Aurelle
Phase NA Terminated
NCT04887831 2025-09-08
PRESERVE3
G1 Therapeutics, Inc.
Phase 2 Terminated
NCT04430036 2024-04-04
AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Terminated
NCT04851834 2022-12-20
NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma
Xennials Therapeutics Australia Pty Ltd
Phase 1/2 Terminated
NCT01126749 2022-02-28
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Eisai Inc.
Phase 1/2 Terminated
NCT01611662 2019-07-29
Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer
Fox Chase Cancer Center
Phase 2 Terminated
NCT02560038 2018-11-28
Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT00268450 2018-07-12
Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery
Medical University of South Carolina
Phase 2 Terminated
NCT00005047 2017-06-08
4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer
SWOG Cancer Research Network
Phase 3 Terminated
NCT00714948 2015-11-16
Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT00635726 2015-10-08
Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer
Hellenic Oncology Research Group
Phase 2 Terminated
NCT01496534 2013-11-27
Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors
Icahn School of Medicine at Mount Sinai
Phase 1 Terminated
NCT00516750 2013-07-10
Gene Expression Profiling in Patients With Invasive Bladder Cancer Receiving Methotrexate, Vinblastine, Doxorubicin, and Cisplatin
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01282333 2013-07-02
Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00237575 2012-05-23
Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer
University of Kentucky
Phase 3 Terminated
NCT00003640 2012-03-06
Transurethral Resection and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT00003642 2012-03-06
Radiation Therapy and Chemotherapy Following Surgery in Treating Patients With Stage II or Stage III Bladder Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated